ClinicalTrials.gg
RecruitingNCT04784572evadoulimUpdated Mar 6, 2024

Assessment of Pain During Intramuscular Injection Delay in Adult Psychiatry

An interventional study of first injection delay and second injection delay in Delayed Antipsychotic Treatment, Pharmacological Factors and Individual Factors, sponsored by Centre hospitalier de Ville-Evrard, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Centre hospitalier de Ville-Evrard, France · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
393
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Since psychiatry is still too often confronted with a dichotomy between psyche and soma, the assessment of pain and anxiety at RMI is still rarely done (Willer et al., 1982). The objective of this exploratory study is to evaluate the influence of pharmacological factors (type of injected molecules, injection frequency, injection site, treatment duration, treatment dose, time since last injection) and individual about the pain perceived when injecting antipsychotic therapy (diagnosis, sex, age, weight, duration of illness, level of anxiety, psychiatric and somatic comorbidity, insight). In the future, this study will develop a suitable procedure to limit pain and anxiety during RMI. Taking these dimensions into account will probably allow a better compliance of patients for this type of care, and thus a decrease in the number of relapses in the long term.

02

Conditions studied

  • Delayed Antipsychotic Treatment, Pharmacological Factors and Individual Factors

Keywords

  • pain -injection
03

In context

Lead sponsor

Centre hospitalier de Ville-Evrard, France is the lead sponsor of 22 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients (Males, Females)
  • Over the age of 18
  • Hospitalized or outpatient
  • Patient affiliated with social security, State Medical Aid (AME)
  • With prescription of antipsychotic delay by intramuscular injection
  • French language mastered
  • Given oral consent to pass the self-assessment scales

Exclusion criteria

Exclusion Criteria:

  • Patients on long-term analgesic treatment, daily
  • Patients with chronic pain with or without analgesic treatment
  • Patient not communicating
  • Pregnant woman, parturint and nursing mother
  • Person deprived of liberty by judicial or administrative decision
  • Minor and person subject to legal protection: guardianship or curatorship
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
393 participants (estimated)

Study arms

  • Other
    First injection delay and second injection delay

    During the first injection, the patient will make 3 scales: END, EVAF and insight and there will be an assessment of induration, redness and swelling done with nurses. During the second injection, the patient will perform the END and EVAF scale and then follow up with a maintenance

    Other: first injection delay and second injection delay

Interventions

  • Otherfirst injection delay and second injection delay

    During the first injection, the patient will make END scale for 5 seconds, EVAF scale for 10 seconds and insight scale for 5 minutes. The second injection the patient will make END scale for 5 seconds and EVAF scale for 10 seconds and then a maintenance.

06

What researchers measure

Primary outcomes

  1. The Digital Scale of Pain (END)

    This scale will assess pain at the injection site before and after intramuscular injection of neuroleptic treatment delay. This scale ranges from 0 (none pain) to 10 (worst possible pain). It will only take 5 seconds for the subject. This scale has good concurrent validity because it is highly correlated with others pain measurement tools (Haefeli \& Elfering, 2006), including the analog visual scale of pain (r=0.95; p\<0.001; Bahreini et al., 2015).

    Time frame: At the first visit during the first injection of treatment delay . It will take 5 seconds

  2. The Digital Scale of Pain (END)

    This scale will assess pain at the injection site before and after intramuscular injection of neuroleptic treatment delay. This scale ranges from 0 (none pain) to 10 (worst possible pain). It will only take 5 seconds for the subject. This scale has good concurrent validity because it is highly correlated with others pain measurement tools (Haefeli \& Elfering, 2006), including the analog visual scale of pain (r=0.95; p\<0.001; Bahreini et al., 2015).

    Time frame: At the second visit during the first injection of treatment delay . It will take 5 seconds

  3. Facial Anxiety Visual Scale (EVAf)

    This scale Assess patient anxiety before and after intramuscular injection of delayed neuroleptic therapy. It was developed by Cao et al., (2017). It is a self-assessment scale of the severity of anxiety representing facial expression during anxiety. Six faces represent different expressions of anxiety: "No anxiety", "Mild anxiety", Mild to Moderate Anxiety, Moderate Anxiety, Moderate to High Anxiety, and High Anxiety.

    Time frame: At the first visit during the first injection of treatment delay . It will take10 seconds.

  4. Facial Anxiety Visual Scale (EVAf)

    This scale Assess patient anxiety before and after intramuscular injection of delayed neuroleptic therapy. It was developed by Cao et al., (2017). It is a self-assessment scale of the severity of anxiety representing facial expression during anxiety. Six faces represent different expressions of anxiety: "No anxiety", "Mild anxiety", Mild to Moderate Anxiety, Moderate Anxiety, Moderate to High Anxiety, and High Anxiety.

    Time frame: At the second visit during the first injection of treatment delay . It will take 10 seconds.

  5. Insight scale (BIS)

    This scale will assess the knowledge of the disease, the insight of patients, prior to intramuscular injection of neuroleptic therapy delay to Visit 1 (V1). This questionnaire developed by Birchwood et al. (1994), translated and validated in French by Linder and Favrod, (2006),will allow a quick self-assessment of the patient's insight. It consists of 8 items with a duration of 5 minutes. The person can choose between 3 answers for each item: "Agree", "In disagreement", "Uncertaine". The score is obtained by adding the score of the items: * Maximum score = 12 - Very good insight * 9 and above = good insight * Minimum score = 0 - No insight

    Time frame: At the first visit during the first injection of treatment delay . It will take5 minutes.

07

Study locations

1 of 1 sites recruiting
  • Ch Ville Evrard
    Neuilly-sur-Marne, 93330, France
    Recruiting
    • Dominique Januel, MBBS · Contact
    • Samir JABRI, BSC · Principal investigator
    • Dominique Januel, MBBS · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Sep 2024, 44 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 5, 2021
StartActual
Jan 22, 2021
Primary completionEst.
Sep 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04784572
Lead sponsor
Centre hospitalier de Ville-Evrard, France
Responsible party
Dominique JANUEL (HEAD OF THE UNIT OF CLINICAL RESEARCH, Centre hospitalier de Ville-Evrard, France) — Principal investigator
First posted
Mar 5, 2021
Start date
Jan 22, 2021
Primary completion
Sep 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 6, 2024

Study contacts

Rusheenthira THAVASEELAN, MSC
Contact
r.thavaseelan@epsve.fr
0143093232
Youcef BENCHERIF, MSC
Contact
y.bencherif@epsve.fr
0143093232

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion